九安医疗(002432) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥301,292,856.79, representing a 99.03% increase compared to ¥151,378,308.04 in the same period last year[3]. - Net profit attributable to shareholders was ¥45,956,809.95, a significant turnaround from a loss of ¥35,317,618.39, marking a 230.12% increase[3]. - Basic earnings per share improved to ¥0.1062 from a loss of ¥0.0816, reflecting a 230.15% increase[3]. - The company reported a net profit of CNY 49,571,188.27, compared to a net loss of CNY 39,516,282.83 in Q1 2019, indicating a turnaround in profitability[25]. - The company expects a net profit of CNY 15,000,000 for the first half of 2020, a turnaround from a loss of CNY 4,972,280 in the same period last year[12]. Cash Flow and Liquidity - The net cash flow from operating activities reached ¥57,534,224.65, up 252.05% from a negative cash flow of ¥37,838,483.42 in the previous year[3]. - Cash and cash equivalents increased by 59.38% to CNY 527,986,255.60 due to higher operating and investment cash inflows[9]. - The cash flow from operating activities was approximately ¥57.53 million, a substantial improvement from a negative cash flow of ¥37.84 million in the same quarter last year[31]. - The company's cash and cash equivalents at the end of the first quarter of 2020 totaled ¥268,127,255.60, up from ¥73,285,805.82 at the beginning of the period, reflecting a net increase of ¥194,841,449.78[32]. - The company reported total cash inflows from financing activities of ¥68,867,857.98, compared to ¥35,443,695.00 in the previous year, indicating a growth of approximately 94%[32]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,173,064,057.36, a 12.00% increase from ¥1,940,253,552.18 at the end of the previous year[3]. - The company's total liabilities rose to CNY 519,580,088.93 from CNY 341,749,509.13, marking an increase of approximately 52%[19]. - The total equity attributable to shareholders increased to CNY 1,715,667,352.48 from CNY 1,662,529,949.38, which is an increase of about 3.2%[20]. - The company's total liabilities increased to CNY 110,454,527.65 from CNY 51,881,986.96, reflecting a rise in financial obligations[23]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 83,246[6]. - The largest shareholder, Shihezi Sanhe Equity Investment Partnership, held 30.49% of the shares, totaling 131,980,702 shares[6]. Research and Development - Research and development expenses increased by 69.72% to CNY 27,131,120.13, reflecting higher investment in internet and medical business[9]. - Research and development expenses for Q1 2020 were approximately ¥10.74 million, slightly up from ¥10.37 million in the same period last year, reflecting continued investment in innovation[27]. Government Support - The company received government subsidies amounting to ¥123,087.73 during the reporting period[4]. - The company’s deferred income rose by 375.61% to CNY 10,074,197.89, primarily from government subsidies related to assets[9]. Operational Highlights - Total revenue for the period reached CNY 301,292,856.79, a 99.03% increase driven by the sales of temperature measurement products[9]. - Operating costs for Q1 2020 amounted to CNY 248,223,062.76, up from CNY 200,261,945.94, reflecting a rise in operational expenses[24]. - The company plans to leverage its channel and certification advantages to expand exports of medical supplies during the pandemic[12].